# Seth M. Pollack

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/seth-m-pollack/

## Facts

| Field | Value |
| --- | --- |
| Citations | 5,180 |
| Field | Sarcoma Diagnosis and Treatment |
| h-index | 35 |
| i10-index | 72 |
| Last Known Institution | Northwestern University |
| OpenAlex ID | https://openalex.org/A5026451121 |
| ORCID iD | 0000-0002-2466-0607 |
| Works | 303 |

## Researcher papers

- [Soft Tissue Sarcoma, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology](https://scholariq.org/papers/soft-tissue-sarcoma-version-2-2022-nccn-clinical-practice-guidelines-in-oncology/)
- [Afamitresgene autoleucel for advanced synovial sarcoma and myxoid round cell liposarcoma (SPEARHEAD-1): an international, open-label, phase 2 trial](https://scholariq.org/papers/afamitresgene-autoleucel-for-advanced-synovial-sarcoma-and-myxoid-round-cell/)
- [T‐cell infiltration and clonality correlate with programmed cell death protein 1 and programmed death‐ligand 1 expression in patients with soft tissue sarcomas](https://scholariq.org/papers/t-cell-infiltration-and-clonality-correlate-with-programmed-cell-death-protein-1/)
- [Mobilization of CD8+ T Cells via CXCR4 Blockade Facilitates PD-1 Checkpoint Therapy in Human Pancreatic Cancer](https://scholariq.org/papers/mobilization-of-cd8-t-cells-via-cxcr4-blockade-facilitates-pd-1-checkpoint/)
- [Systemic Interferon-γ Increases MHC Class I Expression and T-cell Infiltration in Cold Tumors: Results of a Phase 0 Clinical Trial](https://scholariq.org/papers/systemic-interferon-increases-mhc-class-i-expression-and-t-cell-infiltration-in/)
- [Assessment of Doxorubicin and Pembrolizumab in Patients With Advanced Anthracycline-Naive Sarcoma](https://scholariq.org/papers/assessment-of-doxorubicin-and-pembrolizumab-in-patients-with-advanced/)
- [NCCN Guidelines® Insights: Gastrointestinal Stromal Tumors, Version 2.2022](https://scholariq.org/papers/nccn-guidelines-insights-gastrointestinal-stromal-tumors-version-2-2022/)
- [Novel Therapeutic Approaches in Chondrosarcoma](https://scholariq.org/papers/novel-therapeutic-approaches-in-chondrosarcoma/)
- [NY‐ESO‐1 is a ubiquitous immunotherapeutic target antigen for patients with myxoid/round cell liposarcoma](https://scholariq.org/papers/ny-eso-1-is-a-ubiquitous-immunotherapeutic-target-antigen-for-patients-with/)
- [Pancreatic Ductal Adenocarcinoma Contains an Effector and Regulatory Immune Cell Infiltrate that Is Altered by Multimodal Neoadjuvant Treatment](https://scholariq.org/papers/pancreatic-ductal-adenocarcinoma-contains-an-effector-and-regulatory-immune-cell/)
- [County-level socioeconomic, race-ethnicity, household, and infrastructure vulnerability associations with bone cancer treatment and prognosis in the US](https://scholariq.org/papers/county-level-socioeconomic-race-ethnicity-household-and-infrastructure/)

## Researcher topics

- [Sarcoma Diagnosis and Treatment](https://scholariq.org/topics/sarcoma-diagnosis-and-treatment/)
- [CAR-T cell therapy research](https://scholariq.org/topics/car-t-cell-therapy-research/)
- [Immunotherapy and Immune Responses](https://scholariq.org/topics/immunotherapy-and-immune-responses/)
- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [Cancer Research and Treatments](https://scholariq.org/topics/cancer-research-and-treatments/)

## Researcher university

- [Northwestern University](https://scholariq.org/institutions/northwestern-university/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.